Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma ; volume:6 ; number:1 ; day:19 ; month:6 ; year:2018 ; pages:1-7 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (19.6.2018), 1-7, 12.2018
- Creator
-
Domingo-Musibay, Evidio
- Contributor
-
Murugan, Paari
Giubellino, Alessio
Sharma, Sandeep
Steinberger, Daniel
Yuan, Jianling
Hunt, Matthew A.
Lou, Emil
Miller, Jeffrey S.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0357-3
- URN
-
urn:nbn:de:101:1-2018082822000415750124
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Domingo-Musibay, Evidio
- Murugan, Paari
- Giubellino, Alessio
- Sharma, Sandeep
- Steinberger, Daniel
- Yuan, Jianling
- Hunt, Matthew A.
- Lou, Emil
- Miller, Jeffrey S.
- SpringerLink (Online service)
Other Objects (12)
A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report
A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Pembrolizumab as first-line treatment for metastatic uveal melanoma
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report
A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Pembrolizumab as first-line treatment for metastatic uveal melanoma
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report
A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Pembrolizumab as first-line treatment for metastatic uveal melanoma
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers